U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H27O8.Na
Molecular Weight 406.4034
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM ARTESUNATE

SMILES

C[C@]1([H])CC[C@@]2([H])[C@@]([H])(C)[C@]([H])(OC(=O)CCC(=O)[O-])O[C@@]3([H])[C@]42[C@@]1([H])CC[C@](C)(O3)OO4.[Na+]

InChI

InChIKey=ZISJLHQNEVGTIU-RFEYTNPVSA-M
InChI=1S/C19H28O8.Na/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19;/h10-13,16-17H,4-9H2,1-3H3,(H,20,21);/q;+1/p-1/t10-,11-,12+,13+,16-,17-,18-,19-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H27O8
Molecular Weight 383.4136
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

treatment of falciparum malaria since 1990. It is a potent antimalarial drug that can reduce parasitaemia by 90% within 24 h of administration. Sodium artesunate was first isolated in China, it is a water soluble antimalaria used clinically in China.

CNS Activity

Curator's Comment:: Active metabolite of artesunate was detected in CSF after intravenous administration of artesunate.

Originator

Sources: http://adisinsight.springer.com/drugs/800023198https://www.ncbi.nlm.nih.gov/pubmed/8891104Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (1982), 2, (2), 99-103.
Curator's Comment:: Indicated originators are originators of Dihydroartemisinin/piperaquine formulation. Originator of Dihydroartemisinin is unknown.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Sodium artesunate

Approved Use

Plasmodium falciparum malaria
Curative
Eurartesim

Approved Use

Eurartesim tablets (piperaquine tetraphosphate in combination with dihydroartemisinin) are indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants aged ≥6 months and weighing ≥5kg.

Launch Date

1319587200000
Curative

Approved Use

Although not FDA-approved for use in the United States, artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinidine.
Curative
Primary
Primary
Primary
Primary
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
3.3 μg/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.5 μg × h/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.7 μg × h/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.3 h
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.3 h
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7%
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Other AEs: Anemia, Transaminases increased...
Other AEs:
Anemia (65%)
Transaminases increased (27%)
Thrombocytopenia (18%)
Hyperbilirubinemia (14%)
Acute renal failure (10%)
Leukocytosis (10%)
Acute respiratory distress syndrome (8%)
Lymphopenia (7%)
Neutropenia (5%)
Disseminated intravascular coagulation (3%)
Creatinine increased (3%)
Pneumonia (3%)
Pulmonary edema (3%)
Diarrhea (3%)
Sources:
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea (grade 1, 45%)
Dizziness (grade 1, 52%)
Vomiting (grade 1, 26%)
Convulsions (grade 1, 3%)
Bradycardia (grade 1, 23%)
Sources:
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Other AEs: Acute renal failure, Hemoglobinuria...
Other AEs:
Acute renal failure (8.9%)
Hemoglobinuria (6.7%)
Jaundice (2.3%)
Sources:
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
DLT: Nausea, Vomiting...
Dose limiting toxicities:
Nausea (grade 3, 1 patient)
Vomiting (grade 3, 1 patient)
ALT increased (grade 3-4, 1 patient)
Neutropenic infection (grade 3-4, 1 patient)
Sources:
18 mg/kg 2 times / 3 weeks multiple, intravenous
MTD
Dose: 18 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 18 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
DLT: Hypersensitivity reaction...
Dose limiting toxicities:
Hypersensitivity reaction (grade 3, 1 patient)
Sources:
12 mg/kg 2 times / 3 weeks multiple, intravenous
Studied dose
Dose: 12 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
DLT: Neutropenic fever...
Dose limiting toxicities:
Neutropenic fever (grade 3, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acute renal failure 10%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Leukocytosis 10%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Hyperbilirubinemia 14%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Thrombocytopenia 18%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Transaminases increased 27%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Creatinine increased 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Diarrhea 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Disseminated intravascular coagulation 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Pneumonia 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Pulmonary edema 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Neutropenia 5%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Anemia 65%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Lymphopenia 7%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Acute respiratory distress syndrome 8%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Bradycardia grade 1, 23%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Vomiting grade 1, 26%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Convulsions grade 1, 3%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Nausea grade 1, 45%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Dizziness grade 1, 52%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Jaundice 2.3%
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Hemoglobinuria 6.7%
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Acute renal failure 8.9%
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Nausea grade 3, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Vomiting grade 3, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
ALT increased grade 3-4, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Neutropenic infection grade 3-4, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Hypersensitivity reaction grade 3, 1 patient
DLT
18 mg/kg 2 times / 3 weeks multiple, intravenous
MTD
Dose: 18 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 18 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Neutropenic fever grade 3, 1 patient
DLT
12 mg/kg 2 times / 3 weeks multiple, intravenous
Studied dose
Dose: 12 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
weak [IC50 32.3 uM]
weak [IC50 75.4 uM]
yes
yes
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Antimalarial agents, 2. Artesunate, an inhibitor of cytochrome oxidase activity in Plasmodium berghei.
1986 Jan-Feb
[Effects of sodium artesunate on electrical properties and Na+,K(+)-ATPase activities of mouse small intestine].
1990 Jul
Effects of sodium artesunate, a new antimalarial drug, on renal function.
2001 Mar
Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand.
2002 Nov
Diuretic effect of sodium artesunate in patients with malaria.
2002 Nov
Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.
2003 Jan
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
2003 Sep
Randomized control trial of quinine and artesunate in complicated malaria.
2004 Apr
Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.
2005 Feb-Apr
Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
2005 Jan-Feb
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.
2007 Dec 21
Treatment of experimental nephrotic syndrome with artesunate.
2007 Jul-Aug
Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.
2008 Nov 6
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
2009 Jul
The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.
2009 Sep 2
Factors determining sensitivity or resistance of tumor cell lines towards artesunate.
2010 Apr 15
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
2010 May
Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.
2010 Oct 21
Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells.
2014 Aug 5
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.
2014 Jan 20
Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue.
2014 Oct
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells.
2015 Oct 19
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Oral route is possible: One group of 45 patients received 400 mg of Sodium artesunate on the first day of treatment and then 200 mg daily for 4 days for a total of 1200 mg (group I: 5-day treatment). A second group of 46 patients received 400 mg of Sodium artesunate on the first day of treatment and then 200 mg daily for 6 days for a total of 1600 mg (group II: 7-day treatment). 5- or 7-day regimens of sodium artesunate with a total dose of 1200-1600 mg are effective and safe in treating falciparum malaria acquired in Thailand.
Eurartesim (piperaquine tetraphosphate (PQP)/
Route of Administration: Oral
dihydroartemisinin at micromolar dose levels exhibits a dose- and time-dependent cytotoxicity in ovarian cancer cell lines.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:48:41 UTC 2021
Edited
by admin
on Fri Jun 25 22:48:41 UTC 2021
Record UNII
CN5E49Z611
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM ARTESUNATE
Common Name English
SM-804
Code English
ARTESUNATE SODIUM SALT
MI  
Common Name English
ARTESUNATE SODIUM SALT [MI]
Common Name English
BUTANEDIOIC ACID, MONO((3R,5AS,6R,8AS,9R,10S,12R,12AR)-DECAHYDRO-3,6,9-TRIMETHYL-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL) ESTER, SODIUM SALT
Common Name English
SM 804
Code English
Code System Code Type Description
PUBCHEM
44410736
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY
CAS
82864-68-4
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY
MERCK INDEX
M2078
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY Merck Index
EPA CompTox
82864-68-4
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY
EVMPD
SUB21911
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY
DRUG BANK
DBSALT001279
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY
FDA UNII
CN5E49Z611
Created by admin on Fri Jun 25 22:48:41 UTC 2021 , Edited by admin on Fri Jun 25 22:48:41 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE